Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
Get Alerts KZR Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. EST.
A webcast of the event may be accessed at the “Events & Presentations” section of Kezar’s website at https://www.kezarlifesciences.com/investors/news-events/ir-calendar. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis, and polymyositis. Additionally, KZR-261, is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005274/en/
Gitanjali Jain
Vice President, Investor Relations and External Affairs
650-269-7523
[email protected]
Kimberly Minarovich
Argot Partners
212-600-1902
[email protected]
Source: Kezar Life Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Momentus Inc. (MNTS) Receives Nasdaq Deficiency Notice
- Ameriserv Financial (ASRV) Reaches Cooperation Agreement with Significant Shareholder SB Value Partners, L.P.
- Exicure Inc. (XCUR) Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!